Form 4: Corcept Therapeutics Executive William Guyer Reports Stock Option Exercise and Sale

William Guyer, Chief Development Officer of Corcept Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• On March 4, 2025, William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options to acquire 20,000 shares of common stock at a price of $19.26 per share.
• Simultaneously, Guyer sold 20,000 shares of common stock at $59.07 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on November 27, 2024.
• Following these transactions, Guyer directly owns 5,487 shares of Corcept Therapeutics common stock.
• Guyer also holds options to purchase 170,000 additional shares.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the executive's outlook on the company.

Positives

• The exercise of stock options demonstrates the executive's belief in the company's future prospects.
• The pre-arranged 10b5-1 trading plan ensures compliance with insider trading regulations.

Negatives

• The sale of shares by an executive could be perceived negatively by some investors, although it is part of a pre-planned strategy.

Risks

• Executive stock sales, even under 10b5-1 plans, can sometimes create short-term price volatility.
• Changes in executive holdings are always subject to investor interpretation and sentiment.

Future Outlook

The document does not contain specific forward-looking statements, but it details ongoing stock option exercises and sales under a pre-arranged plan.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often scrutinized by investors for insights into company performance and management confidence. The use of 10b5-1 plans is a standard practice to avoid insider trading concerns.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options to align management interests with shareholder value.
• Companies like Gilead Sciences and Amgen also utilize stock options as part of their executive compensation plans.
• The vesting schedules and exercise prices are generally benchmarked against industry peers to attract and retain talent.

Stakeholder Impact

• Shareholders may react to the stock sale, although it is part of a pre-defined plan.
• Employees may view the executive's actions as a reflection of the company's performance.

Key Dates